Key Takeaways
- Spanish authorities are trying to improve transparency in reimbursement by publishing reports that give an overview of information that supported decisions to reimburse new medicines on the national health system.
- Three reports on CSL Behring’s Hemgenix, BMS’ Camzyos (mavacamtent) and Pfizer’s Velsipity have so far been published.
In a bid to improve transparency, the Spanish health ministry has started publishing reports on how decisions were taken to reimburse new medicines on the National Health System (SNS).
Three reports have so far been published and shed more light on the agreements between authorities and manufacturers to secure financing. A report on CSL Behring’s one-time gene therapy Hemgenix...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?